The Effects of Exosomes in Otitis Media With Effusion

Eye & ENT Hospital of Fudan University

Status: Unknown

Conditions: Otitis Media With Effusion; Adenoid Hypertrophy

Treatments: Procedure: Adenoidectomy

Study type: Observational

Funder types: Other

Identifiers

NCT05402267

OME-2022

Details and patient eligibility

About

The particularity of adenoids, as a reservoir of bacterial pathogens and immune molecules, is known to be significantly involved in children with otitis media with effusion (OME). As an important carrier of intercellular substance transfer and signal transduction, exosomes with different biological functions can be secreted by different types of cells. There remains significant uncertainty regarding the clinical transmitter of exosomes to OME, especially in its pathophysiologic development. In this study, the investigators try to elucidate the biological functions of exosomes in children with adenoid hypertrophy accompanied by OME.

Patients with adenoid hypertrophy or otitis media will be separated into three groups: those with adenoid hypertrophy, with otitis media and with adenoid hypertrophy and otitis media both, as well as a healthy control group. Participants in the four groups will have their middle ear effusion, nasopharyngeal secretion, and peripheral blood samples taken, from which exosomes will be separated for further analysis. Adenoidectomy will be conducted in adenoid hypertrophy accompanied by OME and adenoid hypertrophy alone and their adenoid tissue will be collected. Blood will be collected again 3 months after surgery and middle ear and nasopharyngeal examinations will be performed. Exosomes will be isolated for follow-up studies as before surgery. Investigators will also use proteome research, exosome biomarkers, and high-throughput sequencing to examine the pathophysiology of OME, particularly inflammation-related etiology, in order to provide novel ideas for OME diagnosis and treatment.

Full description

This study will explore the pathogenesis of OME by detecting the exosome in middle ear fluid, nasopharyngeal secretions and peripheral blood in order to identify areas of opportunity for future research and to provide a theoretical basis for drug development for the treatment of secretory otitis media.

240 subjects will be recruited from Eye and ENT hospital of Fudan University or the community. They will be divided into four groups: adenoid hypertrophy accompanied by OME (group OA, n=60), adenoid hypertrophy alone (group CA, n=60), OME alone (group CO, n=60) and healthy control group (children without OME or adenoid hypertrophy, n=60). All participants will undergo the examinations of middle ear and nasopharynx in addition to blood collection when they get into the groups. The exosomes will be isolated form middle ear effusions, nasopharyngeal secretions/adenoid tissue, and peripheral blood collected from all participants. The OA and CA groups will undergo adenoidectomy and their adenoid tissue will be collected. Blood will be collected again 3 months after surgery and middle ear and nasopharyngeal examinations will be performed. Exosomes will be isolated for follow-up studies as before surgery.

The primary outcome measures will be (1) ANOVA of the alterations and related gene expression of exosome contents in nasopharyngeal secretions in the four groups; (2) microbial alterations and the exosomes from biofilm on the surface of the adenoids in OA and CA groups preoperative and postoperative; and (3) the differences of exosomes from peripheral blood samples in OA and CA groups preoperative and postoperative.

Enrollment: 240 estimated patients

Sex: All

Ages: 4 to 10 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

OME-Adenoid (OA) group:

1. Children aged between 4 and 10 years old.
2. Diagnosis of chronic otitis media with effusion, and the course of disease is at least 3 months.
3. There are varying degrees of hearing loss. PTA (The mean hearing threshold of 500Hz, 1000Hz and 2000Hz) ≥ 30dB.
4. Nasopharyngeal lateral X-ray showing A/N > 0.6 of adenoids.

Control-Adenoid (CA) group:

1. Children aged between 4 and 10 years old.
2. Nasopharyngeal lateral X-ray showing A/N > 0.6 of adenoids.

Control-OME (CO) group:

1. Children aged between 4 and 10 years old.
2. Diagnosis of chronic otitis media with effusion, and the course of disease is at least 3 months.
3. There are varying degrees of hearing loss. PTA (The mean hearing threshold of 500Hz, 1000Hz and 2000Hz) ≥ 30dB.

Exclusion criteria

1. Patients who have had one or more episodes of otitis media in the previous one year.
2. Any immunologic diseases.
3. Any intrinsic diseases of hearing system, anatomic or physiologic defect of the ear.
4. Pharmacologic abnormality.

Trial design

240 participants in 4 patient groups

OA: OME-Adenoid group

Description:

Patients who meet the follow inclusion criteria will be considered eligible as the OME-Adenoid (OA) group

Treatment:

Procedure: Adenoidectomy

CA: Control-Adenoid group

Description:

Patients who meet the follow inclusion criteria will be considered eligible as the Control-Adenoid (CA) group

Treatment:

Procedure: Adenoidectomy

CO: Control-OME group

Description:

Patients who meet the follow inclusion criteria will be considered eligible as the Control-OME (CO) group

control group

Description:

Patients without OME and adenoid hypertrophy will be considered eligible as the control group